Scancell Holdings Plc (SCLP)

Overview

Scancell Holdings plc is a trailblazing biopharmaceutical entity immersed in the clinical stage, pioneering in the innovative domain of immunotherapies and vaccines aimed at the confrontation of cancer and infectious diseases. Founded in 1997 and rooted in Oxford, United Kingdom, the company leverages cutting-edge scientific research to develop groundbreaking treatments. Through its dedication to advancing immunotherapy, Scancell Holdings plc embodies a beacon of hope in transforming cancer treatment paradigms and combating emerging infectious threats.

Products and Services

• SCIB1

  An ImmunoBody cancer vaccine currently progressing through Phase II clinical trials, SCIB1 targets the treatment of metastatic melanoma. This pioneering approach harnesses the body's immune system to recognize and combat cancer cells, representing a novel stride within oncologic therapeutics.

• SCIB2/iSCIB2

  In the evaluation phase for patients with solid tumors, including non-small cell lung cancer, SCIB2/iSCIB2 vaccine embodies a groundbreaking immunotherapy angle. It aims to unlock the potential of the immune system in recognizing and destructing tumors, underscoring Scancell's dedication to expanding the frontier of cancer treatment.

• Modi-1

  A vaccine comprising citrullinated peptides, Modi-1 is currently undergoing phase I/II clinical trials for the treatment of various solid tumors including triple negative breast, ovarian, renal, and head and neck cancers. This innovative modality illustrates the company's pursuit of targeting cancer through unique antigenic determinants, offering a glimpse into the future of personalized cancer vaccines.

• Modi-2

  Targeting homocitrullinated cancer antigens, Modi-2 represents another facet of Scancell's strategy in exploiting distinctive cancer characteristics for therapeutic gain. Through this approach, the company endeavors to broaden its impact on cancer care, bringing novel treatment options to patients with dire needs.

• SCOV1 and SCOV2 COVIDITY

  As part of its portfolio expansion into infectious diseases, Scancell is developing a DNA vaccine against the SARS-CoV-2 virus. SCOV1 and SCOV2 COVIDITY venture into the realm of pandemic response, reflecting Scancell's adaptive strategy in leveraging its immunotherapy expertise to address global health emergencies.